Luke Jelen
Medical Research Council (MRC) Clinical Research Training Fellow at King’s College London
Data updated
Research Footprint
Luke Jelen appears in 7 tracked papers (2016–2023), most studied alongside Ketamine, MDMA and Esketamine, across Depressive Disorders, Anxiety Disorders and Safety & Risk Management.
Most-cited paper: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (1057 citations).
Frequent co-authors: Allan Young, James Rucker and James Stone.
Background & Research
Luke A. Jelen is a psychiatry researcher associated with King’s College London’s Institute of Psychiatry, Psychology & Neuroscience and the NIHR Maudsley Biomedical Research Centre. His published work includes reviews and meta-analyses on ketamine, psychedelic drug trials, and treatment options for depression and anxiety, often collaborating with Allan H. Young, James M. Stone, and colleagues. He has been identified in King’s Research Portal materials as an MRC Clinical Research Training Fellow.
Key Impact
He is a psychiatry researcher whose work spans ketamine, opioids, and psychedelic-assisted treatments in mood and anxiety disorders, including systematic reviews and clinical research on psilocybin and MDMA-related interventions.
Collaboration Network
28 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Luke Jelen is associated with.
King's College London
academicThe Centre for Mental Health Research and Innovation and the Psychoactive Trials Group are actively conducting clinical trials with various psychedelic compounds to develop new care models for treatment-resistant depression, PTSD, and anorexia nervosa.
View stakeholder →South London and Maudsley NHS Foundation Trust
South London and Maudsley NHS Foundation Trust (SLaM) is the UK's leading academic mental health Trust, home to Maudsley Hospital and the NIHR Maudsley Biomedical Research Centre; in partnership with COMPASS Pathways and King's College London's Institute of Psychiatry, it has established a dedicated Psychedelics and Mental Health Research Centre conducting psilocybin Phase 3 trials for treatment-resistant depression, MDMA therapy for PTSD, 5-MeO-DMT studies, and the SIGNATURE synaptic imaging biomarker trial, aiming to treat 650–700 patients over five years.
View stakeholder →